Table 2

Functional construct validity of SDAI response cutpoints (6 months' data; all treatment arms, infliximab + methotrexate and controls, were pooled for the two trials, ASPIRE and ATTRACT; mean±SD). p<0.001 for global test in all cohorts and all analyses

HAQ improvement (change)HAQ reached (status)
SDAI responseASPIREATTRACTNOR-DMARD*ASPIREATTRACTNOR-DMARD*
No response−0.43±0.54−0.25±0.53−0.11±0.401.11±0.631.50±0.650.53±0.42
SDAI50−0.75±0.57−0.51±0.54−0.28±0.380.76±0.601.16±0.670.35±0.35
SDAI70−0.95±0.57−0.76±0.49−0.40±0.450.58±0.550.70±0.580.30±0.33
SDAI85−1.28±0.60−0.73±0.40−0.55±0.540.20±0.320.70±0.640.16±0.30
  • * Physical disability measured by mHAQ.

  • mHAQ, modified Health assessment questionnaire; NOR-DMARD, Norwegian disease modifying antirheumatic drug prescription dataset; SDAI, simplified disease activity index;